Covid-19 Morbidity amongst Covishield Vaccinated Vs Non-Vaccinated: A Comparative Study

Vikas  Yadav; Poninder  Kumar; Arvind  Kushal; Renu  Yadav; Priya  Anjali

doi:10.5455/njcm.20211014065554

Authors

Vikas Yadav Department of Community Medicine, Medical branch, Sukna, Darjeeling
Poninder Kumar Department of Ophthalmology, Medical branch, Sukna, Darjeeling
Arvind Kushal Hospital Management, Medical branch, Sukna, Darjeeling
Renu Yadav Department of Pharmacology, AFMC, Pune
Priya Anjali Department of Dental, CDU, Darjeeling

DOI:

https://doi.org/10.5455/njcm.20211014065554

Keywords:

Covid-19, Covishield vaccine, herd immunity, fully immunized, non-vaccinated

Abstract

Introduction: Covid-19 pandemic is further spreading its leg in India. Indigenous Covishield vaccination drive was started to protect people from the disease.

Objective: This observational cross sectional study was conducted to assess the morbidity and mortality pattern amongst Covishield vaccinated people Vs non-vaccinated patients of covid19.

Methodology: This observation study was conducted in a dedicated covid-19 hospital. All RTPCR covid-19 patients were included. The data on vaccination against covid-19 amongst the patients was obtained, and analysed using statistical software.

Results: The study population comprised of 155 cases of confirmed covid-19 patients of which 24 (15.48%) were fully vaccinated, however 41 (26.45%) and 90 (58.06%) were partially and non-vaccinated respectively. Fully vaccinated people were protected from development of severe form of disease (X2=9.57, d.f=2, p=0.0083). Mortality was significantly less amongst vaccinated group (X2=4.83, d.f=1, p= 0.028).

Conclusion: Patients who are completely vaccinated with Covishield vaccine are protected from development of severe form of diseases and deaths and hence mass vaccination of Indian population to overcome the pandemic is required at the earliest.

References

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med . 2020 Mar 26 :1199–207.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497–506.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med . 2020 Feb 20

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565–74.

Zhu N, Zhang D, Wang W, et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.

Rawat K, Kumari P, Saha L. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. Vol. 892, European Journal of Pharmacology. Elsevier B.V.; 2021. p. 173751.

Bhadra A, Mukherjee A, Sarkar K. Impact of population density on Covid-19 infected and mortality rate in India. Model Earth Syst Environ . 2021 Mar 1;7(1):623–9.

COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers [Internet]. [cited 2021 May 15]. Available from: https://www.who.int/news-room/commentaries/detail/covid-19-and-the-use-of-angiotensin-converting-enzyme-inhibitors-and-receptor-blockers

Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID-19 and treatment with NSAIDs and corticosteroids: Should we be limiting their use in the clinical setting? Ecancermedicalscience. 2020 Mar 30;14.

Government of India Ministry of Health and Family Welfare revised guidelines for home isolation of mild/asymptomatic covid-19 cases [Internet]. [cited 2021 May 15]. Available from https://www.icmr.gov. in/ctechdocad.html

Government of India Ministry of Health and Family Welfare Protocol for Management of Covid-19 in the Paediatric Age Group.

Government of India, Ministry of health and family welfare, Protocol for mangement of adult Covid-19 patients. [cited 2021 May 15]. Available from: https://www.icmr.gov.in/pdf/covid/techdoc/COVID19 Management_Algorithm 22042021_v1.pdf

Tregoning JS, Brown ES, Cheeseman HM, Flight KE, Higham SL, Lemm NM, et al. Vaccines for COVID-19. Vol. 202, Clinical and Experimental Immunology. Blackwell Publishing Ltd; 2020 :p. 162–92.

Al Awaidy S, Al Awaidy ST, Wannous C. Country Level Preparation for the Deployment of COVID-19 Vaccine Report View Project Clinical Characteristics and Outcomes of the first 63 Adult Patients Hospitalized with COVID-19: An experience from Oman View project Chadia Wannous Country Level Preparation for the Deployment of COVID-19 Vaccine. PP Int J Res Stud Med Heal Sci [Internet]. 2021 ;6(2).

Kartoglu UH, Moore KL, Lloyd JS. Logistical challenges for potential SARS-CoV-2 vaccine and a call to research institutions, developers and manufacturers. Vaccine. 2020;38(34):5393–5.

Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses 2020 Feb 25 ;12(3):254.

Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, et al. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Vol. 137, Antiviral Research. Elsevier B.V.; 2017. p. 82–92.

Le T. The COVID-19 vaccine development landscape. [cited 2021 May 15]; Available from: https://doi.org/10.1038/d41573-020-00073-5

Bagcchi S. The world’s largest COVID-19 vaccination campaign. Lancet Infect Dis [Internet]. 2021 Mar 1;21(3):323. Available from: /pmc/articles/PMC7906682/

Ujjainia R, Tyagi A, Sardana V, Naushin S, Bhatheja N, Kumar K, et al. 13Effect Monitoring and Insights from Vaccination program of Healthcare Workforce from a tertiary level hospital in India against SARS-CoV-2. medRxiv. 2021 Apr 17 ;2021.02.28.21252621.

Thiagarajan K. Covid-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust. Vol. 372, The BMJ. BMJ Publishing Group; 2021

Kataria S, Sharma P, Deswal V, Kumar K, Singh M, Alam S, et al. A Real World Evaluation of the safety and immunogenicity of the Covishield vaccine, ChAdOx1 nCoV- 19 Corona Virus Vaccine (Recombinant) in Health Care Workers (HCW) in National Capital Region (NCR) of India: A preliminary report. medRxiv. 2021 Apr 20 ;2021.04.14.21255452.

Pandya K, Das VK, Mathew MB, Nagar H. Post Vaccination Symptoms among the Beneficieries of Covid Vaccine in Dadra & Nagar Haveli. Int J Dent Med Sci Res; 3(1):1215

Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M., CMMID COVID-19 working group, & Eggo, R. M. (2020). Age-dependent effects in the transmission and control of COVID-19 epidemics. Nature medicine, 26(8), 1205–1211.

Kang, S. J., & Jung, S. I. (2020). Age-Related Morbidity and Mortality among Patients with COVID-19. Infection & chemotherapy 52(2), 154–164.

COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature 600, 472–477 (2021).